Last updated: February 19, 2026
Corcept Therapeutics, Inc. (Corcept) sued Sun Pharma Global FZE (Sun Pharma) alleging patent infringement of its orally available selective glucocorticoid receptor (GR) modulator, relacorilant. The litigation concerns the active pharmaceutical ingredient (API) of relacorilant, and its use in treating Cushing's syndrome. This dispute centers on Corcept's U.S. Patent No. 8,586,610, titled "SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS."
What are the Core Allegations?
Corcept alleges that Sun Pharma infringed U.S. Patent No. 8,586,610 by importing, selling, and offering for sale an API that is covered by the patent. Specifically, Corcept claims that Sun Pharma's actions constitute infringement of one or more claims of the '610 patent. The patent covers novel compounds that selectively modulate the GR, offering therapeutic benefits for conditions associated with excessive glucocorticoid activity.
What is the Patented Technology?
U.S. Patent No. 8,586,610, granted on November 19, 2013, claims compounds with the general structure of selective GR modulators. These compounds are designed to inhibit the binding of glucocorticoids to the GR, thereby reducing the downstream effects of excessive cortisol. The patent's claims describe specific chemical structures and their therapeutic uses, primarily focusing on the treatment of Cushing's syndrome, a condition characterized by prolonged exposure to high cortisol levels. Relacorilant is a proprietary compound developed by Corcept that falls within the scope of this patent.
Who are the Parties Involved?
Corcept Therapeutics, Inc. is the plaintiff, a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for metabolic, oncologic, and psychiatric disorders. Sun Pharma Global FZE is the defendant, a pharmaceutical company engaged in the development, manufacturing, and marketing of a broad range of pharmaceutical products.
What is the Legal Basis for the Dispute?
The lawsuit is based on patent infringement under 35 U.S.C. § 271. Corcept asserts that Sun Pharma's activities related to an API that is structurally and functionally equivalent to or directly claimed by the '610 patent constitute infringement. This includes allegations of direct infringement and potentially induced or contributory infringement depending on the specifics of Sun Pharma's product and its intended use.
What is the Status of the Litigation?
The case, filed in the U.S. District Court for the Central District of California, is in its discovery phase. Both parties are exchanging information and evidence related to the patent claims, Sun Pharma's accused product, and infringement and validity defenses.
What are the Key Dates in the Litigation?
- December 17, 2019: Corcept files its complaint against Sun Pharma.
- February 24, 2020: Sun Pharma files its Answer to the Complaint.
- Ongoing: Discovery, including the exchange of interrogatories, document requests, and depositions.
What is the Potential Impact on Corcept Therapeutics?
Successful patent enforcement would prevent Sun Pharma from launching a competing product that infringes the '610 patent, thereby protecting Corcept's market exclusivity for relacorilant in the treatment of Cushing's syndrome. This would safeguard Corcept's revenue streams and its investment in relacorilant's development. Conversely, an unfavorable outcome could lead to market competition and erosion of Corcept's commercial position.
What are the Potential Implications for Sun Pharma?
An adverse ruling could result in injunctions preventing Sun Pharma from marketing its product, significant monetary damages, and potential attorneys' fees. If Sun Pharma prevails, it could gain market access for its product, provided it meets regulatory approval requirements.
What are the Key Legal Arguments?
Corcept's primary argument is that Sun Pharma's accused product directly infringes the claims of U.S. Patent No. 8,586,610. This involves demonstrating that Sun Pharma's API possesses the structural and functional characteristics recited in the patent's asserted claims.
Sun Pharma's defense likely includes arguments challenging the validity of the '610 patent. These defenses could include prior art, obviousness, and insufficient enablement. They may also argue that their product does not infringe the patent, asserting distinctions in chemical structure, manufacturing process, or intended use that place them outside the scope of the patent claims.
What are the Claims in the '610 Patent?
The '610 patent contains multiple claims covering different aspects of the selective GR modulators. While specific claim numbers being asserted are not publicly detailed in initial filings, patent infringement litigation typically focuses on a subset of the patent's claims deemed most relevant to the accused product. These claims generally define the chemical structure of the compounds, methods of synthesizing them, and methods of using them to treat conditions like Cushing's syndrome.
- Claim 1 (Example - Hypothetical Scope): This claim typically defines the core compound structure with specific substituents and stereochemistry that confer selective GR modulation.
- Method of Treatment Claims: These claims would cover the use of the claimed compounds for treating diseases mediated by excessive glucocorticoid signaling, such as Cushing's syndrome.
What is the Commercial Landscape for Relacorilant?
Relacorilant is being developed by Corcept for the treatment of Cushing's syndrome and hypercortisolism. Cushing's syndrome is a rare endocrine disorder with significant unmet medical needs. Corcept has advanced relacorilant through clinical trials and is preparing for potential commercialization. The market for Cushing's syndrome treatments is limited by the rarity of the disease, but effective therapies command significant pricing power.
What is Sun Pharma's Accused Product?
While the exact identity of Sun Pharma's accused product (API) is not explicitly detailed in public filings, it is understood to be a selective GR modulator intended for therapeutic use, likely targeting indications similar to those of relacorilant. The litigation implies that this API falls within the structural and functional claims of Corcept's '610 patent.
What are the Potential Outcomes of the Litigation?
The litigation could result in several outcomes:
- Settlement: The parties may reach a confidential settlement agreement, which could involve licensing, cross-licensing, or other forms of resolution.
- Judgment for Corcept: If Corcept prevails, the court may issue an injunction preventing Sun Pharma from selling its infringing product and award damages.
- Judgment for Sun Pharma: If Sun Pharma prevails, the patent claims may be invalidated, or it may be found not to infringe, allowing Sun Pharma to proceed with its product development and commercialization.
- Dismissal: The case could be dismissed for various procedural reasons.
What are the Risks for Investors?
Investors in Corcept Therapeutics face risks associated with the outcome of this patent litigation. An unfavorable ruling could negatively impact Corcept's stock price and its ability to achieve its commercial objectives. Conversely, a favorable outcome would strengthen Corcept's intellectual property position and support its market exclusivity. Investors in Sun Pharma also face risks, as a loss in this litigation could lead to significant financial penalties and a delay or halt in product launch.
What is the Broader Context of Pharmaceutical Patent Litigation?
Pharmaceutical patent litigation is a critical component of the industry, defining market exclusivity and influencing drug development investment. Disputes often arise around compound patents, method of use patents, and formulation patents. Generic manufacturers frequently challenge innovator patents to gain market entry, while innovator companies vigorously defend their intellectual property to protect their investments and revenue streams. The outcome of such litigation significantly impacts the competitive landscape and pricing of prescription drugs.
Key Takeaways
- Corcept Therapeutics is suing Sun Pharma Global FZE for infringing U.S. Patent No. 8,586,610, which protects its selective glucocorticoid receptor modulator technology, including relacorilant.
- The dispute centers on Sun Pharma's alleged importation, sale, or offer for sale of an API that Corcept claims falls within the scope of its patent claims.
- The '610 patent covers novel compounds designed to modulate the glucocorticoid receptor and treat conditions like Cushing's syndrome.
- The litigation is in the discovery phase in the U.S. District Court for the Central District of California, with potential outcomes including settlement, judgment for either party, or dismissal.
- The resolution of this case will have significant implications for Corcept's market exclusivity for relacorilant and Sun Pharma's ability to launch its competing product.
FAQs
What specific claims of U.S. Patent No. 8,586,610 are at issue in the litigation?
While the exact claims being asserted by Corcept are not publicly detailed in the initial complaint, patent litigation typically focuses on claims covering the chemical structure of the compound, its manufacturing, and its therapeutic uses, particularly for Cushing's syndrome.
Has Sun Pharma filed an Abbreviated New Drug Application (ANDA) related to this product?
The public record does not explicitly state whether Sun Pharma has filed an ANDA for a generic version of relacorilant. However, the allegations of infringement suggest Sun Pharma is developing or marketing an API for a similar therapeutic indication.
What are the potential damages Corcept could seek if it prevails?
If Corcept prevails, potential damages could include lost profits, a reasonable royalty, and in exceptional cases, enhanced damages for willful infringement. The court can also issue an injunction to prevent further infringing activities.
What are the grounds for patent invalidity that Sun Pharma might raise?
Sun Pharma may challenge the validity of Corcept's patent based on grounds such as anticipation by prior art, obviousness over existing knowledge, lack of enablement, or other defects in patentability requirements.
What is the typical timeline for patent infringement litigation of this nature?
Patent infringement litigation can be lengthy, often taking several years to resolve through trial and potential appeals. The discovery phase itself can last 12-18 months, followed by claim construction, pre-trial motions, and potentially a trial.
Citations
[1] Complaint for Patent Infringement, Corcept Therapeutics, Inc. v. Sun Pharma Global FZE, No. 2:19-cv-15678 (C.D. Cal. Dec. 17, 2019).
[2] U.S. Patent No. 8,586,610 (filed Feb. 27, 2013).
[3] Answer to Complaint, Corcept Therapeutics, Inc. v. Sun Pharma Global FZE, No. 2:19-cv-15678 (C.D. Cal. Feb. 24, 2020).
